References
- Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:2295–303.
- Schorge JO, Modesitt SC, Coleman RL, et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol 2010;119:7–17.
- Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009;361:170–7.
- Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. PNAS 2011;108:18032–7.
- Screening for Ovarian Cancer: Clinical Summary of U.S. Preventive Services Task Force Reaffirmation Recommendation. AHRQ Publication 2012; 12–05165-EF-5. Accessed 31 March 2014 from: http://www.uspreventiveservicestaskforce.org/uspstf12/ovarian/ovarcancersum.htm
- Anderson GL, McIntosh M, Wu L, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010;102:26–38.
- Yurkovetsky Z, Skates S, Lomakin A, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010;28:2159–66.
- Ware Miller R, Smith A, DeSimone CP, et al. Performance of the American College of Obstetricians and Gynecologists’ ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol 2011;117:1298–306.
- Lopez J, Percharde M, Coley HM, et al. The context and potential of epigenetics in oncology. Br J Cancer 2009; 100:571–77.
- Guo SW, Zilberberg MD, Hummelshoj L. Endometriosis and ovarian cancer. Lancet Oncol 2012;13:e189–90; author reply e190.
- Chen H, Hardy TM, Tollefsbol TO. Epigenomics of ovarian cancer and its chemoprevention. Front Genet 2011;2:1–8. doi: 10.3389/fgene.2011.00067
- Creighton CJ, Fountain MD, Yu Z, et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res 2010;70:1906–15.
- Resnick KE, Alder H, Hagan JP, et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009;112:55–9.
- Kuhlmann JD, Rasch J, Wimberger P, et al. MicroRNA and the pathogenesis of ovarian cancer – a new horizon for molecular diagnostics and treatment? Clin Chem Lab Med 2012;50:601–15.
- Kobayashi H, Yamada Y, Sado T, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan.2008;18:414–20.
- Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327–40.
- Fishman DA, Cohen L, Blank SV, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol 2005;192:1214–21; discussion 1221–22.
- Marret H, Sauget S, Giraudeau B, et al. Contrast-enhanced sonography helps in discrimination of benign from malignant adnexal masses. J Ultrasound Med 2004;23:1629–39; quiz 1641–42.
- Fleischer AC, Lyshchik A, Andreotti RF, et al. Advances in sonographic detection of ovarian cancer: depiction of tumor neovascularity with microbubbles. AJR 2010;194:343–8.